NC
Nexthera Capital Portfolio holdings
AUM
$120M
This Quarter Return
+14.33%
1 Year Return
+20.18%
3 Year Return
+117.79%
5 Year Return
–
10 Year Return
–
AUM
$147M
AUM Growth
+$147M
(-3.9%)
Cap. Flow
-$15.5M
Cap. Flow
% of AUM
-10.51%
Top 10 Holdings %
Top 10 Hldgs %
81.82%
Holding
53
New
13
Increased
4
Reduced
7
Closed
18
Top Buys
| 1 |
Pfizer
PFE
|
$16M |
| 2 |
GSK
GSK
|
$13.3M |
| 3 |
NDRM
NeuroDerm Ltd. Ordinary Shares
NDRM
|
$7.65M |
| 4 |
Vanda Pharmaceuticals
VNDA
|
$7.17M |
| 5 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
$5.32M |
Top Sells
| 1 |
Novartis
NVS
|
$14.4M |
| 2 |
AstraZeneca
AZN
|
$8.2M |
| 3 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$8.09M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
$6.18M |
| 5 |
Neurocrine Biosciences
NBIX
|
$4.64M |
Sector Composition
| 1 | Healthcare | 93.44% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Pfizer
PFE
$141B
| $26.9M | 13.7% | 785,051 +467,000 | +147% | +$16M |
|
|
SHPG
2
DELISTED
Shire pic
SHPG
| $18.1M | 9.25% | 104,000 -26,000 | -20% | -$4.53M |
|
|
CELG
3
DELISTED
Celgene Corp
CELG
| $14.9M | 7.62% | 120,000 -2,000 | -2% | -$249K |
|
|
4
GSK
GSK
$79.9B
| $13.3M | 6.81% | +316,500 | New | +$13.3M |
|
|
ALXN
5
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $10.5M | 5.35% | 86,500 -13,500 | -14% | -$1.64M |
|
|
KITE
6
DELISTED
Kite Pharma, Inc.
KITE
| $8.24M | 4.21% | 105,000 -45,000 | -30% | -$3.53M |
|
|
NDRM
7
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
| $7.65M | 3.9% | +288,000 | New | +$7.65M |
|
|
GBT
8
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $7.54M | 3.85% | 204,500 +144,500 | +241% | +$5.32M |
|
|
9
Vanda Pharmaceuticals
VNDA
$279M
| $7.17M | 3.66% | +512,200 | New | +$7.17M |
|
10
Minerva Neurosciences
NERV
$16.5M
| $6.13M | 3.13% | 757,200 +264,242 | +54% | +$2.14M |
|
11
Aclaris Therapeutics
ACRS
$209M
| $3.33M | 1.7% | +111,500 | New | +$3.33M |
|
|
EIGR
12
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| $3.02M | 1.54% | 263,600 | – | – |
|
|
PRTK
13
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
| $2.89M | 1.47% | 150,000 +50,000 | +50% | +$963K |
|
|
RXDX
14
DELISTED
Ignyta, Inc.
RXDX
| $2.88M | 1.47% | +335,000 | New | +$2.88M |
|
15
Abeona Therapeutics
ABEO
$350M
| $2.47M | 1.26% | 494,064 -74,509 | -13% | -$372K |
|
|
TVRD
16
Tvardi Therapeutics, Inc. Common Stock
TVRD
$281M
| $2.21M | 1.13% | 120,000 -130,000 | -52% | -$2.39M |
|
17
Axsome Therapeutics
AXSM
$6.05B
| $1.56M | 0.8% | +400,000 | New | +$1.56M |
|
|
TIG
18
DELISTED
TiGenix American Depositary Shares
TIG
| $1.44M | 0.73% | +92,203 | New | +$1.44M |
|
|
MRNS
19
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $1.42M | 0.72% | +800,000 | New | +$1.42M |
|
20
Clearside Biomedical
CLSD
$28.9M
| $959K | 0.49% | 120,763 | – | – |
|
|
ZSAN
21
DELISTED
Zosano Pharma Corporation
ZSAN
| $950K | 0.48% | +500,000 | New | +$950K |
|
|
ADXS
22
DELISTED
Advaxis, Inc.
ADXS
| $791K | 0.4% | 96,800 -103,200 | -52% | -$843K |
|
23
Verastem
VSTM
$569M
| $696K | 0.36% | 336,000 | – | – |
|
|
SRRA
24
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $612K | 0.31% | +400,000 | New | +$612K |
|
25
Alkermes
ALKS
$4.78B
| $550K | 0.28% | +9,400 | New | +$550K |
|